Home Midwest Grand Rapids, MI Shoulder Innovations COMPANY
FDA-cleared device company
3 open jobs · last seen Oct 23, 2026 · 10 sources
Profile checked Oct 10, 2026
Keywords: Shoulder Arthroplasty
At a glance HQ Grand Rapids, MI source Region Midwest Stage FDA-cleared device company Latest trial —: Shoulder Innovations Clinical Data Registry (Oct 23, 2024) source Timeline Sep 8, 2026 FDA FDA 510(k) clearance: N22 Offset Humeral Head — K262173, Sep 8, 2026. Applicant at approval: Shoulder Innovations, Inc. source ↗ Jun 29, 2026 Debt Debt financing: $50M (up to, as announced), announced Jun 29, 2026. Source: SEC filing. source ↗ Apr 13, 2026 FDA FDA 510(k) clearance: InSet Reverse Total Shoulder System — K254128, Apr 13, 2026. Applicant at approval: Shoulder Innovations, Inc. source ↗ Jan 15, 2026 FDA FDA 510(k) clearance: N22 EZ Glenosphere — K252516, Jan 15, 2026. Applicant at approval: Shoulder Innovations, Inc. source ↗ Sep 26, 2025 FDA FDA 510(k) clearance: Inset Reverse Total Shoulder System — K252221, Sep 26, 2025. Applicant at approval: Shoulder Innovations, Inc. source ↗ Jul 31, 2025 Raise IPO: amount not published, announced Jul 31, 2025. Source: company's own press page. source ↗ Jul 21, 2025 Debt Debt: $40M (not counted as a raise), announced Jul 21, 2025. Source: company's own press page. source ↗ Mar 10, 2025 Raise Private equity round — Series E: $40M (total, as published), announced Mar 10, 2025. Source: company's own press page. source ↗ Feb 11, 2025 FDA FDA 510(k) clearance: InSet Total Shoulder System — K241817, Feb 11, 2025. Applicant at approval: Shoulder Innovations, Inc. source ↗ Oct 23, 2024 Trial start —: Shoulder Innovations Clinical Data Registry source ↗ Upcoming milestones 2039-12 (ESTIMATED) · · Shoulder Innovations Clinical Data Registry · NCT06754150 Estimated primary completion per ClinicalTrials.gov. Dates move.
Funding Raised: $40.0M · Debt: $90.0M. Last 2 years.
Jul 31, 2025 IPO: amount not published, announced Jul 31, 2025. Source: company's own press page. source ↗ Mar 10, 2025 Private equity round — Series E: $40M (total, as published), announced Mar 10, 2025. Source: company's own press page. source ↗ Jun 29, 2026 Debt financing: $50M (up to, as announced), announced Jun 29, 2026. Source: SEC filing. source ↗ Jul 21, 2025 Debt: $40M (not counted as a raise), announced Jul 21, 2025. Source: company's own press page. source ↗ Clinical trials (lead sponsor) 1 Record Title Phase Status Start Primary completion NCT06754150 Shoulder Innovations Clinical Data Registry Not listed Recruiting Oct 23, 2024 2039-12 (estimated)
FDA records (last 2 years) Sep 8, 2026 FDA 510(k) clearance: N22 Offset Humeral Head — K262173, Sep 8, 2026. Applicant at approval: Shoulder Innovations, Inc. source ↗ Apr 13, 2026 FDA 510(k) clearance: InSet Reverse Total Shoulder System — K254128, Apr 13, 2026. Applicant at approval: Shoulder Innovations, Inc. source ↗ Jan 15, 2026 FDA 510(k) clearance: N22 EZ Glenosphere — K252516, Jan 15, 2026. Applicant at approval: Shoulder Innovations, Inc. source ↗ Sep 26, 2025 FDA 510(k) clearance: Inset Reverse Total Shoulder System — K252221, Sep 26, 2025. Applicant at approval: Shoulder Innovations, Inc. source ↗ Feb 11, 2025 FDA 510(k) clearance: InSet Total Shoulder System — K241817, Feb 11, 2025. Applicant at approval: Shoulder Innovations, Inc. source ↗ Open jobs 3 Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.
Connect See your connections at Shoulder Innovations on LinkedIn (search by name, results not checked) LinkedIn shows your 1st and 2nd-degree connections here from your own login, including who could introduce you. Radar doesn't see your connections.
LinkedIn page linked from the company's own site: source · seen 2026-10-12
